Merck KGaA buys Silence in $1.3B RNA drug deal
Merck KGaA pays $1.3 billion for UK RNA drugmaker Silence Therapeutics and its Phase 2 blood disorder treatment.
Palanor Wire · composed from 3 outlets · every claim links to its sources
What happened
Germany's Merck KGaA agreed to buy UK drug developer Silence Therapeutics for $1.3 billion. 13 The deal adds RNA interference therapeutics to Merck's pipeline. 123 Silence's blood disorder drug passed a Phase 2 test. 2 Silence is developing the siRNA drug divesiran. 3
Why it matters
The drug could threaten a Takeda medicine. 2 The acquisition builds Merck's work in rare and specialty diseases using genetic medicines. 3
What to watch
Regulatory review and potential competition with Takeda's drug will determine the acquisition's value. 2
Sources · 4
[1]Merck KGaA bets on RNAi with $1.3B Silence buyout
BioPharma Dive
[2]Germany's Merck acquires Silence Therapeutics in $1.3 billion RNA drug deal reut.rs/4Baa27H
Reuters · Bluesky
[3]China's Hansoh Pharma strikes drug deal with Roche worth over $15 billion reut.rs/3TPdPXb
Reuters · Bluesky
[4]Merck KGaA to buy Silence Therapeutics and its siRNA pipeline for $1.3B
Endpoints News
Matched signals
Lattice signals Numen pinned to this story at publish time.
No matched signals on this story.
Unlock the analytical widgets on every article — signal matches, Trends snapshots, X overlays, agent reasoning — with a Member account.
Upgrade →On X right now
Top engagement posts about this topic, ranked by likes + retweets + quotes.
No high-engagement X posts captured for this topic. Either the topic is too quiet or the upstream API was unavailable when this article published.
Unlock the analytical widgets on every article — signal matches, Trends snapshots, X overlays, agent reasoning — with a Member account.
Upgrade →Your read
How did this article land?
Three sliders. Optional comment. Anonymous is fine.
Open to anyone. One response per reader.